|
Description
Phase III clinical trials of UCB's antiepileptic drug (AED) in development, brivaracetam, are underway, as adjunctive therapy in patients with refractory partial-onset epilepsy. Rikelta(TM) is the proposed tradename for brivaracetam.
"The start of the Phase III program for brivaracetam is a key milestone in the advancement of UCB's epilepsy franchise and re-enforces our commitment to the development of new treatment options for people with epilepsy," said Iris Loew-Friedrich, MD, PhD, Global Head of Development, UCB. "Today up to 30% of patients can be resistant to current antiepileptic medications and UCB's research and development programmes aim to support this significant unmet medical need."
Nearly 1300 epilepsy... |
More articles from Worldwide Biotech
BIOLINERX REPORTS POSITIVE RESULTS FROM BL-1020 TRIAL.(Clinical report..., December 01, 2007
SNT-MC17 PHASE IIA FOR MUSCULAR DYSTROPHY ENCOURAGING.(Clinical report..., December 01, 2007
SURVIVAL ANALYSIS FROM SATRAPLATIN TRIAL DISAPPOINTING., December 01, 2007
Looking for additional articles?
Click here
to search our database of over 3 million articles.
|
